<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098263</url>
  </required_header>
  <id_info>
    <org_study_id>CAM01</org_study_id>
    <nct_id>NCT04098263</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lumen Bioscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumen Bioscience, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, double-blind, placebo-controlled, dose-escalation study of 3 dose&#xD;
      levels of LMN-101. Healthy volunteers will take LMN-101 or placebo orally either as a single&#xD;
      dose or at one of three dose levels three times daily over 28 days. Protocol-specified&#xD;
      evaluations and procedures will be performed on Days 1-2 and every one-two weeks during&#xD;
      dosing. Study observation will continue until 4 weeks after the last dose of study drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy volunteers will be sequentially assigned to the following dosing regimens:&#xD;
&#xD;
      Part A:&#xD;
&#xD;
      A single, open-label dose of 3000 mg orally (2 subjects)&#xD;
&#xD;
      Part B:&#xD;
&#xD;
      Subjects will be randomized within a dose regimen to active or placebo treatment:&#xD;
&#xD;
        -  300 mg PO TID (three times daily) given as a single 300-mg capsule of LMN-101 orally&#xD;
           three times daily for 28 days (4 subjects) or identical-appearing placebo capsule (2&#xD;
           subjects).&#xD;
&#xD;
        -  1000 mg PO TID given as two 500-mg capsules of LMN-101 orally three times daily for 28&#xD;
           days (4 subjects) or identical-appearing placebo capsules (2 subjects).&#xD;
&#xD;
        -  3000 mg PO TID given as six 500-mg capsules of LMN-101 orally three times daily for 28&#xD;
           days (4 subjects) or identical-appearing placebo capsules (2 subjects).&#xD;
&#xD;
      The primary endpoint is:&#xD;
&#xD;
      • Safety and tolerability of LMN-101.&#xD;
&#xD;
      The secondary endpoints are:&#xD;
&#xD;
        -  Peak serum drug concentration following administration of the initial dose and peak&#xD;
           serum drug concentration following a course of treatment (if systemic absorption is&#xD;
           observed).&#xD;
&#xD;
        -  Area under the serum drug concentration versus time curve (AUC) following administration&#xD;
           of the initial dose and following a course of treatment (if systemic absorption is&#xD;
           observed).&#xD;
&#xD;
        -  Induction of serum anti-drug antibodies (if systemic absorption is observed).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Actual">June 24, 2020</completion_date>
  <primary_completion_date type="Actual">April 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part A: Open Label Part B: Randomized, Double-Blind, Placebo-Controlled</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part B: Identical-appearing placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of adverse events in LMN-101 subjects compared to placebo subjects</measure>
    <time_frame>Day 1 to Day 56</time_frame>
    <description>adverse events graded according to severity and rates compared between LMN-101 subjects and placebo subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of LMN-101: proportion of subjects completing study drug compared to placebo</measure>
    <time_frame>Day 1 to Day 56</time_frame>
    <description>proportion of subjects completing study drug and remaining on study and free from possibly drug-related and dose-limiting serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Peak serum concentration in LMN -101 subjects</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>Peak serum drug concentration in subjects receiving LMN-101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: area under the curve in serum</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>Area under the serum drug concentration versus time curve in subjects receiving LMN-101 at each dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibodies</measure>
    <time_frame>Day 1 to Day 56</time_frame>
    <description>Induction of serum anti-drug IgG antibodies</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Campylobacter Jejuni Infection</condition>
  <arm_group>
    <arm_group_label>Part B: Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 mg PO TID given as a single 300-mg capsule of LMN-101 orally three times daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mg PO TID given as two 500-mg capsules of LMN-101 orally three times daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cohort 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3000 mg PO TID given as six 500-mg capsules of LMN-101 orally three times daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3000 mg PO single dose given as six 500-mg capsules of LMN-101 orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LMN-101</intervention_name>
    <description>variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B: Cohort 1</arm_group_label>
    <arm_group_label>Part B: Cohort 2</arm_group_label>
    <arm_group_label>Part B: Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female between 18 and 50 years, inclusive, at time of informed consent&#xD;
&#xD;
          2. Willingness to participate after written informed consent obtained&#xD;
&#xD;
          3. Available for all planned clinical visits for physical examinations, blood draws,&#xD;
             stool collections&#xD;
&#xD;
          4. General good health, without significant medical illness or abnormal physical&#xD;
             examination findings as determined by the PI.&#xD;
&#xD;
          5. Adequate bone marrow reserve, renal and liver function.&#xD;
&#xD;
               1. Absolute neutrophil count ≥ 1.5 x 10e9/L&#xD;
&#xD;
               2. Lymphocyte count &lt; 6.0 x 10e9/L&#xD;
&#xD;
               3. Platelet count ≥ 150 x 10e9/L&#xD;
&#xD;
               4. Hemoglobin ≥ 110 g/L&#xD;
&#xD;
               5. Estimated glomerular filtration rate ≥ 40 mL/min/1.73 meter squared&#xD;
&#xD;
               6. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 3x upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               7. Total bilirubin ≤ 1.5x ULN&#xD;
&#xD;
               8. Serum albumin ≥ 28 g/L&#xD;
&#xD;
          6. Females of childbearing potential should be using and committed to continue using one&#xD;
             of the following acceptable birth control methods:&#xD;
&#xD;
               1. Sexual abstinence (inactivity) or exclusively same-sex partner for 1 month prior&#xD;
                  to screening through study completion; or&#xD;
&#xD;
               2. Intrauterine device (IUD) in place for at least 1 month prior to study through&#xD;
                  study completion; or&#xD;
&#xD;
               3. Stable hormonal contraception for at least 1 month prior to study through study&#xD;
                  completion; or&#xD;
&#xD;
               4. Surgical sterilization (vasectomy) of male partner at least 6 months prior to&#xD;
                  study.&#xD;
&#xD;
          7. To be considered of non-childbearing potential, females should be surgically&#xD;
             sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least&#xD;
             2 months prior to study) or be post-menopausal and at least 3 years since last menses.&#xD;
&#xD;
          8. Male participants must use condoms during the study and through study completion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with an experimental compound within 30 days.&#xD;
&#xD;
          2. Treatment within 30 days or planned use within the study period with immunomodulator&#xD;
             or immunosuppressant agent.&#xD;
&#xD;
          3. Pregnancy or breastfeeding.&#xD;
&#xD;
          4. Presence of any of the following clinical conditions:&#xD;
&#xD;
               1. History of one or more of the following: cardiac insufficiency (NYHA III/IV),&#xD;
                  uncontrolled cardiac arrhythmias, unstable ischemic heart disease, or&#xD;
                  uncontrolled hypertension (systolic blood pressure &gt; 170 mmHg or diastolic blood&#xD;
                  pressure &gt; 110 mmHg).&#xD;
&#xD;
               2. History of venous thromboembolic disease within 12 months, myocardial infarction,&#xD;
                  or cerebrovascular accident.&#xD;
&#xD;
               3. Unstable pulmonary, renal, hepatic, endocrine or hematologic disease.&#xD;
&#xD;
               4. Gastrointestinal disorder requiring ongoing care by a physician.&#xD;
&#xD;
               5. Autoimmune disease, mixed connective tissue disease, scleroderma, polymyositis,&#xD;
                  or significant systemic involvement secondary to rheumatoid arthritis.&#xD;
&#xD;
               6. Evidence of active malignant disease, malignancies diagnosed within the previous&#xD;
                  5 years, or breast cancer diagnosed within the previous 5 years (except skin&#xD;
                  cancers other than melanoma).&#xD;
&#xD;
               7. Known active current or history of recurrent bacterial, viral, fungal,&#xD;
                  mycobacterial or other opportunistic infections; or major episode of infection&#xD;
                  requiring hospitalization or treatment with IV antibiotics within 4 weeks.&#xD;
&#xD;
               8. Positive serology for human immunodeficiency virus (HIV) infection or history of&#xD;
                  other immunodeficiency illness.&#xD;
&#xD;
               9. Positive serology results for hepatitis B surface antigen (HBsAg) or hepatitis C&#xD;
                  virus (HCV)&#xD;
&#xD;
              10. Significant neuromuscular disease or neuropathy&#xD;
&#xD;
              11. Psychiatric condition&#xD;
&#xD;
              12. Alcohol or illicit drug abuse/dependency or positive urine toxicology screen for&#xD;
                  drugs of abuse other than marijuana. Alcohol and tobacco consumption are&#xD;
                  permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Griffin, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleus Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

